Biodexa Pharmaceuticals (BDRX) Notes Payables (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Notes Payables across 11 years of filings, most recently posting $668356.9 for Q2 2025.

• In Q2 2025, Notes Payables rose 204.32% year-over-year to $668356.9; the TTM figure through Jun 2025 stood at $668356.9 (up 204.32% YoY), while the FY2014 annual figure was $809168.8, down 58.57% from the prior year.
• Notes Payables came in at $668356.9 for Q2 2025 at Biodexa Pharmaceuticals, up from $219626.4 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $668356.9 in Q2 2025 to a low of $181704.7 in Q2 2021.
• Average Notes Payables over 4 years is $319998.4, with a median of $214965.9 recorded in 2024.
• Year-over-year, Notes Payables slumped 95.7% in 2021 and surged 204.32% in 2025.
• Over 4 years, Notes Payables stood at $181704.7 in 2021, then climbed by 15.74% to $210305.5 in 2022, then increased by 4.43% to $219626.4 in 2024, then surged by 204.32% to $668356.9 in 2025.
• Per Business Quant data, the three most recent Notes Payables figures were $668356.9 in Q2 2025, $219626.4 in Q2 2024, and $210305.5 in Q2 2022.